Genes, oxidative stress, and the risk of chronic obstructive pulmonary disease

Hiroshi Koyama, *Duncan M Geddes

Ion Transport Unit, National Heart and Lung Institute, Imperial College, London SW3 6LR, and *Department of Respiratory Medicine, Royal Brompton Hospital, London SW3 6NP, UK

Introductory article

Association between polymorphism in gene for microsomal epoxide hydrolase and susceptibility to emphysema

CAD Smith, DJ Harrison

Background. The first-pass metabolism of foreign compounds in the lung is an important protective mechanism against oxidative stress. We investigated whether polymorphisms in the gene for microsomal epoxide hydrolase (mEPHX), an enzyme involved in this protective process, had any bearing on individual susceptibility to the development of chronic obstructive pulmonary disease (COPD) and emphysema.

Methods. We designed PCR-based genotyping assays to detect variant forms of mEPHX that confer slow and fast activity. We used these assays to screen 203 blood-donor controls and groups of patients with asthma (n = 57), lung cancer (n = 50), COPD (n = 68), and emphysema (n = 94), who were attending specialised clinics in Edinburgh, UK.

Findings. The proportion of individuals with innate slow mEPHX activity (homozygotes) was significantly higher in both the COPD group and the emphysema group than in the control group (COPD 13 [19%] vs control 13 [6%]; emphysema 21 [22%] vs 13 [6%]). The odds ratios for homozygous slow activity versus all other phenotypes were 4.1 (95% CI 1.8–9.7) for COPD and 5.0 (2.3–10.9) for emphysema.

Interpretation. Genetic polymorphisms in xenobiotic enzymes may have a role in individual susceptibility to oxidant-related lung disease. Epoxide derivatives of cigarette-smoke components may be the cause of some of the lung damage characteristic of these diseases. (Lancet 1997;350:630–33)

Chronic obstructive pulmonary disease (COPD) is one of the major causes of premature death in industrialised countries. While its primary pathology is pulmonary emphysema together with narrowing and obliteration of airways, COPD remains a clinical diagnosis characterised by chronic airflow limitation which progresses slowly over a period of years and is largely irreversible.1 The majority of cases are a consequence of chronic cigarette smoking and are thus preventable. However, only a relatively small proportion of smokers develop symptomatic disease.2 As a consequence, there has been considerable interest in identifying those who are most susceptible, and the mechanisms of their susceptibility. A number of studies indicate that genetic factors contribute to the risk of COPD. Alpha-1-antitrypsin deficiency is already well recognised and twin studies have suggested the presence of other undetermined genetic factors.3–6 Identification of these genetic components could provide useful insights into the pathogenesis of COPD in the same way as did recognition of the association between alpha-1-antitrypsin deficiency and COPD.1 This association, together with the fact that emphysema can be produced experimentally by intratracheal instillation of papain, led to the protease-antiprotease hypothesis of pulmonary emphysema.

The introductory article contributes further to the debate. It suggests that genetic susceptibility to oxidative stress may also confer a risk for the development of COPD. This implies that oxidant-antioxidant imbalance, like protease-antiprotease imbalance, may be important in its pathogenesis.4 Indeed, a number of investigators have implicated oxidant-antioxidant interaction in the pathogenesis of smoking induced COPD.5 In brief, smoking increases alveolar oxidants, in part because cigarette smoke itself contains an enormous number of free radicals and in part because it increases the number of inflammatory cells in alveoli which spontaneously release oxidants. These oxidants inactivate alpha-1-antitrypsin and other protease inhibitors such as secretory leukoprotease inhibitor. Furthermore, the recruited inflammatory cells also increase the protease burden, thus tipping the protease-antiprotease balance further towards the protease side. Moreover, oxidants in cigarette smoke can directly damage com-
Harrison investigated whether polymorphisms in the pathway of metabolism involves two main types of specimens from the pathology archives of Edinburgh. S-transferases (GST) or epoxide hydrolases. The relative cancer was then subdivided into those with and those intermediates is therefore protective.

Greater oxidative stress from cigarette smoke and so to highly reactive intermediates such as epoxides by the involved in the metabolism of highly reactive epoxide biotics, including benzo[a]pyrene, a carcinogen containing in tobacco smoke, are enzymatically metabolized to highly reactive intermediates such as epoxides by the cytochrome P450 system. These resultant metabolites may be cytotoxic, mutagenic, and/or carcinogenic. The enzymatic conversion of these metabolites to inactive intermediates is therefore protective.

Epoxides can be detoxified principally by glutathione S-transferases (GST) or epoxide hydrolases. The rel-

University. No clinical data were available for the lung cancer patients but lung function was presumably quite well preserved or they would not have undergone surgery.

This rather odd study design suggests a possible change of direction during the course of the research. It may be that the investigators started by seeking a genetic susceptibility to lung cancer (reactive epoxides are carcinogenic) with negative results, but stumbled on an association between slow metabolisers and COPD. Whatever the primary aim, the outcome was interesting. In brief, the COPD and “emphysema” groups contained significantly more homozygous mutants for the exon 3 (slow) polymorphism than the controls.

Some caution is needed over the interpretation of these findings. While they may indicate a true and novel causal association, the study population was small and the findings could be due to chance. They clearly need to be confirmed in other study populations. Furthermore, the “emphysema” group was unusual, being defined from the morphological anatomy of lung samples resected for cancer. While this is the “purest” way to make such a diagnosis, it provides no clinical information. If these subjects simply had histological evidence of mild emphysema, they may not be satisfactorily representative of smokers in general who are susceptible to COPD.

A second concern is whether biochemical pathways affected by microsomal epoxide hydrolase are actually involved in the pathogenesis of emphysema. Cigarette smoke certainly contains free radicals and multiple other chemicals capable of generating reactive epoxides, and some of these can certainly damage nucleic acids, proteins and lipids. It is not clear, however, whether these processes are important in vivo, how they affect the protease/antiprotease balance or oxidant/antioxidant balance, nor whether epoxide hydrolase is an important rate limiting step in such a process.

The hypothesis that oxidant/antioxidant imbalance is due to polymorphisms of the gene for microsomal epoxide hydrolase is nevertheless an interesting one which deserves further investigation. There are many possible genetic mechanisms for undue susceptibility to cigarette smoke, and it is worth reviewing the range of these in order to put this new observation in perspective.

Genetic contributions to COPD xenobiotic metabolism

Genetically determined variation in xenobiotic detoxification/biotransformation has attracted interest recently as a possible mechanism for observed differences in susceptibility to various conditions—for example, idiosyncratic reactions to pharmacological agents and smoking induced lung cancers. A detailed discussion of the metabolic process of detoxification of xenobiotics is beyond the scope of this review. Briefly, the major pathway of metabolism involves two main types of enzymes: the phase I cytochrome P450 mediating oxidative metabolism, and phase II conjugating enzymes such as glutathione S-transferases. A number of xenobiotics, including benzo[a]pyrene, a carcinogen contained in tobacco smoke, are enzymatically metabolised to highly reactive intermediates such as epoxides by the cytochrome P450 system. These resultant metabolites may be cytotoxic, mutagenic, and/or carcinogenic. The enzymatic conversion of these metabolites to inactive intermediates is therefore protective.

Ejoxides can be detoxified principally by glutathione S-transferases (GST) or epoxide hydrolases. The rel-

Figure 1. Protease-antiprotease balance and oxidant-antioxidant balance.
Xenobiotics

\[
\begin{align*}
\text{Inactive metabolites} & \quad \text{Xenobiotics} \\
\text{P450 and other enzyme systems} & \quad \text{Excretion} \\
\text{Reactive metabolites} & \quad \text{Cytotoxicity/ carcinogenicity}
\end{align*}
\]

Figure 2 Xenobiotic metabolism: activation-inactivation balance.

ative balance between activation and inactivation is thought to underlie susceptibility to the noxious effects of various xenobiotics (fig 2). For example, altered phenotypes and genotypes in the cytochrome P450 isoforms CYP1A1 have been reported to be associated with smoking-induced lung cancer and other cancers. Defective glutathione S-transferases caused by the GST M1 null genotype have also been linked to an increased risk of developing lung cancer, although the results of studies conducted in different ethnic groups have not always been consistent. In addition, individuals with the susceptible genotypes of CYP1A1 have been confirmed to be clinically significant. The clinical effect will depend not only on the kinetics of metabolism but also on the major site of action. Local expression in lungs might well be as important as hepatic metabolism, and so the relationship of the activity of a given enzyme and its clinical consequences is likely to be complex.

DEFICIENCY OF ANTIPROTEASE SCREEN

Alpha-1-antitrypsin deficiency

A number of genetic factors have been proposed to increase the risk for developing COPD, but only a few have been confirmed to be clinically significant. The most important is \( \alpha \)-1-antitrypsin deficiency; the odds ratio for the development of COPD in association with the homozygous ZZ phenotype (presence versus absence) has been calculated at more than 30 (table 1). As \( \alpha \)-1-antitrypsin is a potent inhibitor of neutrophil elastase, the recognition of this association has led to an elastase-antielastase hypothesis (or, more broadly, a protease-antiprotease hypothesis) as a pathogenic explanation for pulmonary embolyses (fig 1). However, as the frequency of this homozygosity is relatively low even in Caucasian populations, the deficiency accounts for less than 1% only of all patients with COPD, although some estimates have been higher. Furthermore, \( \alpha \)-1-antitrypsin deficiency with the PIZZ phenotype is not necessarily associated with COPD and many such

<table>
<thead>
<tr>
<th>Total</th>
<th>MM</th>
<th>MS</th>
<th>MZ</th>
<th>ZZ</th>
<th>SS</th>
<th>SZ</th>
<th>Author</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Controls</td>
<td>2054</td>
<td>1826</td>
<td>82</td>
<td>85</td>
<td>1</td>
<td>2</td>
<td>4</td>
<td>Gulsvik (1979)</td>
</tr>
<tr>
<td></td>
<td>265</td>
<td>17</td>
<td>8</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>Bencze (1985)</td>
</tr>
<tr>
<td></td>
<td>106</td>
<td>94</td>
<td>8</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>Talamo (1972)</td>
</tr>
<tr>
<td></td>
<td>642</td>
<td>583</td>
<td>42</td>
<td>8</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>Barman (1980)</td>
</tr>
<tr>
<td></td>
<td>721</td>
<td>644</td>
<td>57</td>
<td>14</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>Cox (1976)</td>
</tr>
<tr>
<td></td>
<td>919</td>
<td>835</td>
<td>60</td>
<td>21</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>Shigekawa (1976)</td>
</tr>
<tr>
<td></td>
<td>190</td>
<td>146</td>
<td>10</td>
<td>26</td>
<td>5</td>
<td>0</td>
<td>2</td>
<td>Janus (1988)</td>
</tr>
<tr>
<td></td>
<td>114</td>
<td>98</td>
<td>8</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>Kueppers (1977)</td>
</tr>
<tr>
<td></td>
<td>1580</td>
<td>1310.5</td>
<td>110.5</td>
<td>34</td>
<td>0</td>
<td>1</td>
<td>3</td>
<td>Lieberman (1976)</td>
</tr>
<tr>
<td>Total</td>
<td>6318</td>
<td>5630.5</td>
<td>388.5</td>
<td>181</td>
<td>3</td>
<td>4</td>
<td>10</td>
<td></td>
</tr>
</tbody>
</table>

| COPD | 149 | 123 | 14 | 7 | 1 | 0 | 1 | Gulsvik (1979) | Oslo, Norway |
| | 76 | 70 | 4 | 2 | 0 | 0 | 0 | Bencze (1985) | Munich, Germany |
| | 528 | 429 | 34 | 31 | 5 | 0 | 18 | Barman (1980) | Bonn, Germany |
| | 112 | 101 | 1 | 6 | 8 | 0 | 0 | Cox (1976) | Toronto, Canada |
| | 502 | 442 | 35 | 14 | 1 | 2 | 2 | Shigekawa (1976) | New York, USA |
| | 107 | 87 | 6 | 10 | 2 | 0 | 0 | Barnett (1975) | North Carolina, USA |
| | 114 | 97 | 5 | 9 | 3 | 0 | 0 | Kueppers (1977) | Minnesota, USA |
| | 190 | 146 | 10 | 26 | 5 | 0 | 2 | Janus (1988) | Melbourne, Australia |
| | 359 | 275 | 27 | 18 | 10 | 3 | 3 | Lieberman (1976) | California, USA |
| | 123 | 101 | 4 | 6 | 8 | 0 | 0 | Mittmann (1974) | California, USA |
| Total | 1201 | 1054 | 258 | 219 | 12 | 3 | 37 |

| OR | 0.59 | 1.22 | 2.48 | 3.85 | 2.44 | 7.92 |
| OR vs MM | 1.50 | 2.42 | 40.49 | 6.57 | 8.54 | 20.67 |

This table was compiled from studies conducted in different populations using different definitions of the disease. Cases and controls were not matched. Reliable odds ratios cannot therefore be calculated. 1 OR = ratio of each phenotype for COPD against all other phenotypes. 1 OR vs MM = odds ratio of each phenotype against the MM phenotype.
people remain healthy in the absence of a smoking history into their sixth and seventh decades. The heterozygous state of α1-antitrypsin deficiency has also been implicated as a possible risk factor for COPD; the odds ratio for developing COPD in MZ heterozygotes (compared with subjects who are neither heterozygotes nor homozygotes) has been reported by some investigators to range from 1.5 to 5.0 in a review by Standford et al (see also table 1). Furthermore, Tarjan and colleagues have recently accelerated declines in expiratory flow rates and diffusing capacity, as well as increases in total lung capacity and residual volume, in PMZ heterozygous subjects in a longitudinal study. In practice, however, the PMZ state has not been found to pose a major risk for COPD, especially in the absence of smoking. Indeed, several studies in randomly selected populations have failed to demonstrate a definite association between MZ phenotype and COPD, one having had a power of 95% to detect a difference in FEV1/FVC% as low as 3%.

Mutation of the flanking sequence of the α1-antitrypsin gene

A mutation of the 3′ flanking sequence of the α1-antitrypsin gene has been associated with COPD in a few studies. The odds ratios for developing COPD (or emphysema) in association with this mutation (present versus absent) were calculated to be 4.3 and 3.2, respectively. This condition is different from α1-antitrypsin deficiency in that the sequence which codes for the protein itself is normal and the basal serum level of α1-antitrypsin is not reduced. Kaishaker et al suggested that the mutation might diminish the response of the α1-antitrypsin gene to interleukin 6 and thus suppress the acute phase response of α1-antitrypsin. This acute response is thought to counter the increased proteolytic burden at the region of injury induced by inflammation.

Alpha1-antichymotrypsin deficiency

The deficiency of another serine protease inhibitor, α1-antichymotrypsin, has also been shown to be associated with COPD. This counters the adverse enzymic effects of neutrophil cathepsin G, mast cell chymase, and chymotrypsin. Poller et al detected this deficiency in four of 100 patients with COPD but in none of 100 healthy controls. However, there seems to be a wide variation in the prevalence of this deficiency between different populations, as is the case for α1-antitrypsin deficiency, and this abnormality is unlikely to account for a large proportion of patients who develop COPD.

TUMOUR NECROSIS FACTOR-α GENE POLYMORPHISM

A recent study from Taiwan has reported an association between chronic bronchitis and a polymorphism at the -308 position of the tumour necrosis factor α (TNFα) gene. This polymorphism gives rise to two alleles, TNF1 and TNF2. The investigators found that the less common allele, TNF2, which was associated with higher basal and induced expression of TNFα, was more prevalent in patients with chronic bronchitis. They suggested there was an augmented inflammatory process associated with tissue injury due to increased TNFα expression, and hence the development of chronic bronchitis.

The patient group consisted of 42 male adults who had histories of chronic or recurrent productive cough for more than two successive years. There was also airflow limitation defined as FEV1 <80% predicted and FEV1/FVC <69% predicted. Thirteen patients (31%) were non-smokers. No occupational histories were given, and the 13 may have included patients with chronic asthma. Further studies in other populations will be needed to confirm this interesting association.

OTHER FACTORS

Inherited disorders of connective tissue such as Marfan syndrome, Ehlers-Danlos syndrome, and cutis laxa are reported to be associated with a number of pulmonary diseases including emphysema. Abnormal elastic tissue in lungs has been found in necropsy material from infants with Marfan syndrome, and this may explain the association. Blood group-related phenotypes including ABO blood group, ABH secretor/non-secretor, and Lewis positive/negative status have also been focuses of attention, but study results have been inconclusive.

The sex and race of the subjects have also been implicated as possible factors of relevance. The prevalences of COPD and chronic bronchitis are said to be higher in men than in women, for equivalent cigarette consumption, and some studies have shown a greater relative loss of lung function in men than in women. Others suggest that women may be more susceptible than men to the adverse effects of smoking on lung function. Furthermore, some studies have suggested that white males may be more prone to developing COPD, oxidant-antioxidant balance may explain some of the observed differences in susceptibility to various conditions caused by environmental factors, including COPD. Elucidation of additional genetic risk factors may provide useful insights into the pathogenesis of COPD, but clinical benefits are not yet apparent.

The absence of demonstrable risk factors in the individual for developing COPD or lung cancer should not deter physicians from persuading smokers to quit the habit.

LEARNING POINTS

- Only 10–20% of cigarette smokers develop symptomatic COPD, implying undue susceptibility compared with the remainder of the population at large.
- Alpha1-antitrypsin deficiency, which is the only fully established genetic risk factor, accounts for less than 1% of all cases of COPD.
- Polymorphisms for the genes controlling xenobiotic metabolism (hence oxidant-antioxidant balance) may explain some of the observed differences in susceptibility to various conditions caused by environmental factors, including COPD.
- Elucidation of additional genetic risk factors may provide useful insights into the pathogenesis of COPD, but clinical benefits are not yet apparent.
- The absence of demonstrable risk factors in the individual for developing COPD or lung cancer should not deter physicians from persuading smokers to quit the habit.
COPD than non-white males, but neither sex nor race are likely to be major genetic determinants of susceptibility to tobacco smoke.


Genes, oxidative stress, and the risk of chronic obstructive pulmonary disease

H Koyama and DM Geddes

Thorax 1998 53: S10-S14
doi: 10.1136/thx.53.2008.S10

Updated information and services can be found at:
http://thorax.bmj.com/content/53/suppl_2/S10

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/